Ann Epidemiol January 2023 PMID 36404465

Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program.

Hilary A Robbins, Karine Alcala, Elham Khodayari Moez, Florence Guida, Sera Thomas, Hana Zahed, Matthew T Warkentin, Karl Smith-Byrne, Yonathan Brhane, David Muller, Xiaoshuang Feng, Demetrius Albanes, Melinda C Aldrich, Alan A Arslan, Julie Bassett

Full text PDF Download social card

Mentions

Peak: 6 in Nov 2024

across 3 sources since Mar 2022

Extended reach

40,071

potential audience

Total likes

Video views

608

Mentions per month

Mar 2022 – Dec 2024

Where it's discussed

X / Twitter12 posts
News2 articles
YouTube1 videos

AI synopsis

What people are saying

The overall tone is one of positive acknowledgment, with comments like ‘Published in @AnnalsOfEpi!’ and using hashtags such as #biomarkers and #earlydetection indicating interest. The mention of the publication as a significant development during Lung Cancer Awareness Month underscores its relevance, while references to methodological details show moderate engagement and recognition of its potential to impact lung cancer screening practices.

AgreementModerate agreement

Most discussions acknowledge the importance of the publication, with some emphasizing its relevance to lung cancer research and early detection.

InterestHigh interest

The high interest score reflects active engagement and curiosity, evidenced by reactions highlighting the publication’s innovative approach and relevance during Lung Cancer Awareness Month.

EngagementModerate engagement

Posts reference specific aspects like biomarker discovery and methodological considerations, showing a moderate level of thoughtful engagement.

ImpactModerate impact

Participants imply that the research could influence future screening and diagnostic strategies, indicating a recognized potential impact.

Abstract in brief

The INTEGRAL program is a project funded by the NCI that aims to improve lung cancer screening using low-dose CT scans.
It focuses on two main projects: one to find specific proteins in the blood that could help identify people who should get screened and the other to help tell if lung nodules are harmful or not.
They studied thousands of proteins in people with a history of smoking to create a special panel that measures 21 important proteins to help detect lung cancer earlier.

Read the full abstract

All mentions

Lung Cancer Cohort Research and Biomarker Discovery Efforts

This video introduces the Lung Cancer Cohort Consortium (LC3), a vast database with risk factor and clinical info from over 3 million participants, including 70,000 lung cancer cases, to advance research on lung cancer…

IARC WHO · Nov 29, 2024 608 views

Hilary Robbins

@hilaryarobbins · X